BC Extra | Oct 5, 2018
Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene could enable repeat dosing of a gene therapy by suppressing the host’s immune response against the viral vector in...
BC Innovations | Jan 4, 2018
Translation in Brief

RNA replaces enzymes

Moderna Therapeutics Inc. is continuing to build its pipeline of RNA alternatives to enzyme replacement therapies with a compound to treat the rare metabolic disease MMA. The goal is to provide more predictable kinetics and...
BC Week In Review | May 19, 2017
Clinical News

Selecta's gene therapy improves survival in MMA mice

Selecta Biosciences Inc. (NASDAQ:SELB) said its Anc80-synMUT gene therapy corrected methylmalonyl CoA mutase (MUT) mutations and led to survival benefits in mouse models of methylmalonic acidemia (MMA). Selecta licensed the Anc80 vector on which the...
Items per page:
1 - 3 of 3